Philippe Camus, M.D.

Dijon, France

Back to drug

The Drug-Induced Respiratory Disease Website

II.a

Left ventricular dysfunction/failure

De novo chronic, progressive or acute LV dysfunction/failure. May result from myocarditis or eosinophilic myocarditis. May cause congestive heart failure and/or pulmonary edema (see under II). Hypertension may be present. Symptoms range from worsening of preexisting LVF to acute cardiogenic pulmonary edema, shock or cardiopulmonary arrest. See also pulmonary edema under IId, and XIId, XIIf. Review at PMID 10193711, 16808550, 18083403, 21930637

Publications

Chino H, Amano Y, Yamauchi Y, Matsuda J, Takeda N, Tanaka G, Takai D, Nagase T

Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.

Journal of thoracic disease 2016 Sep;8;2646-2650 — 2016 Sep — 2646-2650

Hawkes EA, Okines AF, Plummer C, Cunningham D

Cardiotoxicity in patients treated with bevacizumab is potentially reversible.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Jun 20;29;e560-2 — 2011 Jun 20 — e560-2